Looking Ahead For the Treatments of R/R MM

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

Now Viewing

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

Treatments of R/R MM

The treatment landscape for R/R MM is evolving rapidly, with new therapies on the horizon. Health care professionals must stay informed about these emerging trends to offer the best patient outcomes. Key developments include the following:

• Novel Drug Classes and Mechanisms: New drug classes, such as BCMA-targeted therapies, bispecific antibodies, and chimeric antigen receptor T-cell therapies, are showing promise in improving responses for patients with R/R MM. Understanding their mechanisms and integration into treatment protocols is essential.
• Personalized Treatment Approaches: Advances in genomics and molecular profiling are enabling more personalized treatment plans. Physicians should consider utilizing genetic and biomarker testing to tailor therapies that are most effective for individual patients.
• Combination Therapies: Combining new agents with standard treatments may enhance efficacy. Physicians must remain vigilant in assessing the safety and effectiveness of these combinations.
• Managing Adverse Effects: As newer treatments enter the market, managing novel adverse effects becomes critical. Continuous monitoring and patient education on potential adverse events will be necessary.
• Clinical Trial Involvement: Participation in clinical trials provides patients access to cutting-edge therapies. Physicians should actively discuss trial options with eligible patients.

How Health Care Professionals Can Prepare:

• Stay updated with ongoing clinical trials and drug approvals.
• Gain expertise in novel therapies and their specific indications.
• Advocate for and facilitate personalized treatment plans.
• Be proactive in educating patients about emerging options and potential adverse effects.
• Integrate interdisciplinary collaboration to ensure comprehensive care.

Conclusion

As the landscape of R/R MM treatments evolves, health care professionals need to be agile in their knowledge and application of emerging therapies, ensuring that patients receive the most advanced care available.